CXCR4 and non-small cell lung carcinoma: Among other things, a Phase I trial of plerixafor with chemotherapy in advanced NSCLC was able to show improved response rates as well as prolonged DFS in patients with high CXCR4-expressing tumors (Nengroo et al., 2022a).